Commercializing biotechnology in China

I recently had the opportunity to conduct a brief interview with Mireille Gingras, Ph.D. President and CEO of HUYA Bioscience on doing business with and in China: Tell me about HUYA and what makes the company unique? HUYA Bioscience International has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S. and […]


Drug Patent Expirations in September 2008

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in September 2008 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ANDRODERM Watson Labs testosterone 4,855,294 Sep 6, 2008 AVITA Mylan Bertek tretinoin 5,045,317 Sep 3, 2008 DDAVP Sanofi Aventis Us desmopressin acetate 5,047,398 Sep 10, 2008 OPANA ER Endo Pharms oxymorphone […]


Contract research helps keep drug pipeline flowing

Guest content from Turner Investment Partners‘ Heather Flick McMeekin, Frank Sustersic, Vijay Shankaran, and Theresa Hoang: Contract research helps keep drug pipeline flowing Imagine a new-product development process that typically lasts 10 to 15 years, has only a one in 5,000 chance of succeeding, and costs at least $800 million. That’s the daunting reality that […]


Building Biotechnology 3rd Edition now available

Building Biotechnology: Business, Regulations, Patents, Law, Politics, Science 460 pages Hardcover: 978-09734676-5-9 Softcover: 978-09734676-6-6 Third Edition August, 2008 Homepage The definitive primer and leading textbook on the business of biotechnology is now available in its third edition. This new edition is over 100 pages longer than the second edition and adds new chapters, new figures […]


Beyond the Business Plan: Managing unexpected risk in biotechnology business development

Here’s a slideshow of a talk I recently gave at the Johns Hopkins biotechnology MS/MBA program. The purpose is to illustrate the elements which are important to consider after penning your business plan, and to help position oneself to be prepared for unexpected risks. The material is largely drawn from my book, Building Biotechnology. Go […]


Drug Patent Expirations in August 2008

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in August 2008 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ADVAIR DISKUS 100/50 Glaxosmithkline fluticasone propionate; salmeterol xinafoate 4,992,474 Aug 12, 2008 ADVAIR DISKUS 100/50 Glaxosmithkline fluticasone propionate; salmeterol xinafoate 5,126,375 Aug 12, 2008 ADVAIR DISKUS 100/50 Glaxosmithkline fluticasone propionate; salmeterol […]


Roche and Genentech's mating dance — This isn't the first time

Roche has floated an offer to acquire Genentech, a move which has raised a flurry of questions about the sustainability of the big Pharma business model, Genentech’s future independence, and the value of Genentech. It it worth noting, however, that Roche already bought (and sold) Genentech. Using an excerpt from Building Biotechnology to illustrate, Roche […]


Roche and Genentech’s mating dance — This isn’t the first time

Roche has floated an offer to acquire Genentech, a move which has raised a flurry of questions about the sustainability of the big Pharma business model, Genentech’s future independence, and the value of Genentech. It it worth noting, however, that Roche already bought (and sold) Genentech. Using an excerpt from Building Biotechnology to illustrate, Roche […]


Background: The Clinical and Translational Science Awards Consortium (CTSA program)

Guest content from Christopher Starr: After years of confusion and neglect, translational research is now becoming institutionalized. Citing the barriers between the lab and clinic, along with the difficulties and complexities of conducting clinical research, the NIH set up a major program to advance clinical and translational research. The Clinical and Translational Science Awards consortium, […]


Why the market does not like Flurizan

Guest content from Nicolaj H. Nielsen, managing director of Biostrat. A case-study on the recent licensing-deal between Myriad and Lundbeck: Information asymmetry, calculated bets and royalties in the biotech industry. The share-price of Lundbeck has fallen with approximately 10 %, since the Danish pharmaceutical company announced an inlicensing deal with the US biotech company Myriad […]


Do NOT follow this link or you will be banned from the site!
Get email updates

Get new actionable insights and updates from BiotechBlog